Vhi Medical Group, Pa Internal Medicine Medicare: Medicare Enrolled Practice Location: 6416 Sherman Peak Ct, Castle Pines, CO 80108 Phone: 248-891-1268 |
Onpoint Medical Group, Llc Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 7280 Lagae Rd Ste J, Castle Pines, CO 80108 Phone: 303-814-0505 Fax: 303-814-6491 |
Canyon Ridge Integrated Health Clinic/Center - Multi-Specialty Medicare: Medicare Enrolled Practice Location: 7280 Lagae Rd Ste B, Castle Pines, CO 80108 Phone: 303-660-3505 |
Prca Pc Castle Pines Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 250 Max Dr Ste 102, Castle Pines, CO 80108 Phone: 303-649-3350 Fax: 303-649-3378 |
Canyon Ridge Integrative Health Llc Clinic/Center - Multi-Specialty Medicare: Not Enrolled in Medicare Practice Location: 7280 Lagae Rd Ste B, Castle Pines, CO 80108 Phone: 303-660-3505 |
Vpc Medical Group, Inc. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 6416 Sherman Peak Ct, Castle Pines, CO 80108 Phone: 239-357-6135 |
Castle Pines Family Practice, Llc Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 7280 Lagae Rd, Castle Pines, CO 80108 Phone: 303-814-0505 |
For The Family Medical Care, Pllc Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 7437 Village Square Dr Ste 115, Suite 100, Castle Pines, CO 80108 Phone: 720-695-4852 |
Castle Pines Family Practice Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 7280 Lagae Rd Ste J, Castle Pines, CO 80108 Phone: 303-814-0505 Fax: 303-914-6491 |
News Archive
Healthcare Realty Trust Incorporated today announced results for the fourth quarter ended December 31, 2009. Funds from operations ("FFO," as defined by the National Association of Real Estate Investment Trusts, "NAREIT") per diluted common share for the three months ended December 31, 2009 totaled $0.35, compared with $0.49 for the three months ended December 31, 2008.
Scientists at Johns Hopkins have created a nanoparticle that carries two different antibodies capable of simultaneously switching off cancer cells' defensive properties while switching on a robust anticancer immune response in mice.
The Scottish Medicines Consortium, which advises NHS Scotland on prescribing new treatments, announced today that XTANDI (enzalutamide) is accepted for unrestricted use within NHS Scotland for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.
The approach came in 2009, in a presentation to doctors by Allscripts Healthcare Solutions of Chicago, a well-connected player in the lucrative business of digital medical records.
Immunocompromised mice, created by inactivating the genes that would allow them to recognize and attack donor cells or organs, are critical for studies of bone marrow reconstitution.
› Verified 9 days ago